Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Flagged first, then by citations

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 701–800 of 883

Assessment of the cytotoxic and mutagenic potential of the Jialu River and adjacent groundwater using human-hamster hybrid cells
Wang, X., Zhao, G., Wang, H., Liang, J., Xu, S., Chen, S., Xu, A., & Wu, L. (2017) · Journal of Environmental Sciences · doi:10.1016/j.jes.2017.11.023 · Cited by 3
Activation of p53–p21 is closely associated with the acquisition of resistance to apoptosis caused by β1-integrin silencing in head and neck cancer cells
Kim, M. R., Chang, H. W., Nam, H. Y., Han, M. W., Moon, S. Y., Kim, H. J., Lee, H. J., Roh, J., Kim, S. W., & Kim, S. Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.007 · Cited by 3
p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas
Bałon, B., Kaznowska, E. B., Ignatov, A., Steć, A., Semczuk‐Sikora, A., Schneider‐Stock, R., Jóźwik, M., Sulkowski, S., Cybulski, M., Szumiło, J., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2615 · Cited by 3
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
Taja‐Chayeb, L., Vidal-Millán, S., Gutiérrez, O., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Chávez-Blanco, A. D., la Cruz-Hernández, E. N. D., & Dueñas‐González, A. (2009) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-7-97 · Cited by 3
The code structure of the p53 DNA-binding domain and the prognosis of breast cancer patients
Sato, K., Hara, T., & Ohya, M. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt497 · Cited by 3
Porcine cancer models for translational oncology
Sieren, J. C., Quelle, D. E., Meyerholz, D. K., & Rogers, C. S. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.969626 · Cited by 3
The Somatic Nature of Cancer Allows It to Affect Highly Constrained Genes
Ostrow, S. L., & Hershberg, R. (2016) · Genome Biology and Evolution · doi:10.1093/gbe/evw110 · Cited by 3
Regulatory network involving miRNAs and genes in serous ovarian carcinoma
Zhao, H., Xu, H., & XUE, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6927 · Cited by 3
Proteasome Inhibitors in Cancer Therapy and their Relation to Redox Regulation
Sarı, G., Okat, Z., Şahin, A., & Karademir-Yilmaz, B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190201120013 · Cited by 3
Bayesian evolutionary hypernetworks for interpretable learning from high-dimensional data
Kim, S., Ha, J.-W., Kim, H., & Zhang, B. (2019) · Applied Soft Computing · doi:10.1016/j.asoc.2019.05.004 · Cited by 3
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
Fountzilas, E., Kotoula, V., Koliou, G.-A., Giannoulatou, E., Gogas, H. J., PAPADIMITRIOU, C. A., Tikas, I. S., Zhang, J., Papadopoulou, K., Zagouri, F., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27338 · Cited by 3
The network of SARS-CoV-2—cancer molecular interactions and pathwaysPreprint
Erola, P., Martin, R. M., & Gaunt, T. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.04.487020 · Cited by 3
Uncertainty-assisted virtual immunohistochemical detection on morphological staining via semi-supervised learning
Zhou, S., Jin, Y., Li, J., Zhou, J., Lu, L., Gui, K., Jin, Y., Sun, Y., Chen, W., Chen, Q., et al. (2024) · Optics and Lasers in Engineering · doi:10.1016/j.optlaseng.2024.108657 · Cited by 2
Causality-aware graph neural networks for functional stratification and phenotype prediction at scale
Triantafyllidis, C. P., & Aguas, R. J. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00567-1 · Cited by 4
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2
Identification of a novel TP53 germline mutation in a large Italian Li—Fraumeni syndrome Family
Capra, V., Consales, A., Nozza, P., Monti, P., Inga, A., & Fronza, G. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21796 · Cited by 2
Li-Fraumeni Syndrome
Ganguly, A. A., & Chen, Z. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_28 · Cited by 2
Somatic Mutations in TP53 Gene in Colombian Patients With Non-melanoma Skin Cancer
Gutiérrez-Castañeda, L. D., Nova, J. A., & Cerezo-Cortés, M. I. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10084 · Cited by 2
GBP5 and ACSS3: two potential biomarkers of high-grade ovarian cancer identified through downstream analysis of microarray data
Mitra, A., Ghosh, S., Porey, S., & Mal, C. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2069866 · Cited by 2
Possible relationship between the somatic mutations and the formation of cancers
Cao, Y. (2022) · BIO Web of Conferences · doi:10.1051/bioconf/20225501009 · Cited by 2
The expression level of ARF and p53 in AML patients, and their relation to patients' outcome
Nabil, R., Elshazly, S. S., Hassan, N. M., & Nooh, H. A. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00410-4 · Cited by 3
Value of TMEM115 as a Potential Prognostic Biomarker in Liver Hepatocellular Carcinoma
Kim, H.-R., & Kim, J. (2023) · Gyemyeong uidae haksulji · doi:10.46308/kmj.2023.00220 · Cited by 2
Generation of allogenic chimera carrying mutations in PDX1 and TP53 genes via phytohemagglutinin-mediated blastomere aggregation in pigs
Nguyen, T.-V., Takebayashi, K., Kim, L. T., Namula, Z., Wittayarat, M., Nagahara, M., Hirata, M., Otoi, T., & Tanihara, F. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00870-x · Cited by 2
TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome
Bakry, D., & Malkin, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_10 · Cited by 2
TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers
Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_8 · Cited by 2
Self-citation
Comparison of DGGE and immunohistochemistry in the detection of TP53 variants in a Brazilian sample of sporadic breast tumors
Aguiar, V. R. C., Cordeiro-Silva, M. D. F., de Carvalho, A. A., & Louro, I. D. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0440-4 · Cited by 2
Functional Analysis of Chromodomain Helicase DNA Binding Protein 2(CHD2) mediated Genomic Stability
Rajagopalan, S. (2010) · Cited by 2
The Role of Mutation and Epimutation in the Development of Human Disease
Rivenbark, A. G., & Coleman, W. B. (2009) · Molecular pathology library · doi:10.1007/978-0-387-89626-7_5 · Cited by 2
Familial Breast Cancer and Genetic Predisposition in Breast Cancer
Walavalkar, V., Khan, A. A., & Kandil, D. H. (2015) · Molecular pathology library · doi:10.1007/978-1-4939-2886-6_2 · Cited by 2
Cancer Genetics in the Clinic
Bunz, F. (2016) · Springer eBooks · doi:10.1007/978-94-017-7484-0_8 · Cited by 2
Arrayed Primer Extension Microarrays for Molecular Diagnostics
Tõnisson, N., Oitmaa, E., Krjutškov, K., Pullat, J., Lind, I., Leego, M., Kurg, A., & Metspalu, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374537-8.00017-1 · Cited by 2
Lack of an Association between a Functional Polymorphism in the MDM2 Promoter and Breast Cancer in Women in Northeast Iran.
Afshari, Z. T., Nikpoor, A. R., Afshari, J. T., Ganjali, R., Atigh, P. S. G., Shandiz, F. H., & Jamialahmadi, K. (2017) · Europe PMC (PubMed Central) · Cited by 2
Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model
Salari, A., Thomay, K., Lentes, J., Ebersold, J., Hagedorn, M., Skawran, B., Davenport, C., Schambach, A., Schlegelberger, B., & Göhring, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25581 · Cited by 3
In‐silico identification of frequently mutated genes and their co‐enriched metabolic pathways associated with Prostate cancer progression
Singh, A. N., & Sharma, N. (2021) · Andrologia · doi:10.1111/and.14236 · Cited by 2
TP53 Mutations in Breast Cancer: Association with Ductal Histology and Early Relapse of Disease
Brankovic-Magic, M. V., Jankovic, R. N., Dobričić, J., Borojević, N., Magić, Z., & Radulovic, S. S. (2008) · The International Journal of Biological Markers · doi:10.1177/172460080802300303 · Cited by 2
A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancerPreprint
Shuaibi, A., Chitra, U., & Raphael, B. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.24.590995 · Cited by 2
Drug Response Modeling across Cancers: Proteomics vs. TranscriptomicsPreprint
Zheng, Z., Huang, L., Wang, F., Liu, L., Yu, J., Xie, W., Chen, X., Li, X., & Wong, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.04.626700 · Cited by 2
Biochemical Pathways in Cancer
Breuer, E.-K. Y., Murph, M. M., & Craven, R. J. (2012) · Biochemistry Research International · doi:10.1155/2012/268504 · Cited by 1
Developmental-status-aware transcriptional decomposition establishes a cell state panorama of human cancers
Luo, Y., & Liang, H. (2024) · Genome Medicine · doi:10.1186/s13073-024-01393-6 · Cited by 1
Experimental kinetic mechanism of P53 condensation-amyloid aggregation
Borkosky, S. S., Peralta-Martinez, R., Armella-Sierra, A., Esperante, S., Lizárraga, L., García‐Pardo, J., Ventura, S., Sanchez, I. E., & Gay, G. D. P. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.04.009 · Cited by 1
Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes
Zhong, X., Zhu, X., Ma, X., Zhou, L., Luo, X., Li, P., Ding, Y., Fu, J., Bo, J., Yang, M., et al. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152388 · Cited by 1
Making Sense of Missense: Assessing and Incorporating the Functional Impact of Constitutional Genetic Testing
Weaver, M. S. (2025) · Children · doi:10.3390/children12111449 · Cited by 1
Risk stratification for survival and transformation into acute myeloid leukemia in patients with myelodysplastic syndrome based on the pathogenicity assessment of TP53 mutations
Bug, D. S., Zhogolev, D., Tsvirko, K., Tcvetkov, N., Barkhatov, I., Наркевич, А. Н., Тишков, А., Morozova, Е. V., Petukhova, N. V., & Kulagin, A. (2025) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2025-32-3-95-103 · Cited by 1
Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic database
McGough, S. F., Lyalina, S., Incerti, D., Huang, Y., Tyanova, S., Mace, K., Harbron, C. G., Copping, R., Narasimhan, B., & Tibshirani, R. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341355 · Cited by 1
Genetic analysis of the TP53 and EGFR genes in head and neck cancers
Ebihara, Y., Iwai, M., Yoshida, M., Ando, M., Asakage, T., Yamasoba, T., & Murakami, Y. (2011) · Toukeibu Gan · doi:10.5981/jjhnc.37.1 · Cited by 1
Quand les mutants de p53 se livrent à des trafics !
de Fromentel, C. C., & Maguer‐Satta, V. (2010) · médecine/sciences · doi:10.1051/medsci/20102610814 · Cited by 2
Polymorphism of a DCT gene fragment sequence between the dog and the raccoon dog and its potential effect on binding of transcription factors – in silico analysis of a sequenced fragment
Kowalczyk, M., Jakubczak, A., Horecka, B., Gryzińska, M., & Jeżewska-Witkowska, G. (2016) · Israel Journal of Ecology and Evolution · doi:10.1080/15659801.2016.1195074 · Cited by 1
Interpretation of Tongue Squamous Cell Carcinoma via Protein-Protein Interaction Network Construction and Analysis
Azodi, M. Z., Rezaei–Tavirani, M., Tavirani, M. R., Mansouri, V., & Vafaee, R. (2018) · International Journal of Cancer Management · doi:10.5812/ijcm.62004 · Cited by 1
The Prognostic Significance of c-Met and p53 Immunohistochemical Expression in Gastric and Colorectal Carcinomas
Abou-Bakr, A. A.-E., Abdelaziz, A. A., Malash, I., Mansour, O. M., Abdelsalam, I. M., Abo-Elazm, O. M., Ibrahim, H. A., Mohammed, M., & Khairy, R. A. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.5910 · Cited by 1
Clinicopathologic diagnosis of dVIN related vulvar squamous cell carcinoma: An extended appraisal from a tertiary women's hospital
Wang, T., Baloda, V., Harinath, L., Jones, T. E., Zhang, H., Bhargava, R., & Zhao, C. (2023) · Gynecology and Obstetrics Clinical Medicine · doi:10.1016/j.gocm.2023.01.004 · Cited by 1
Discovery of the prognostic marker in the whole blood sample of gestational trophoblastic neoplasia beyond immunohistochemical tissue markers: mdm2
(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.004 · Cited by 1
Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer
Kadamb, R., & Singh, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16034-9.00003-4 · Cited by 1
ASPP1/2 positive patients with invasive breast cancers have good prognosis
Wang, C., Li, K., An, J., Lv, X., Ma, W., Wang, Y., Meng, N.-L., Tian, Y., & Zhao, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20613 · Cited by 1
Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy
Gim, G., & Badri, N. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2023.90 · Cited by 1
PLK1 Inhibitors Exhibit Potent Preclinical Activity in Platinum-Sensitive and Resistant Small Cell Lung Cancer Models
Toktogonov, D., Isayeva, A., & Kadyrov, R. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/vbnoidzidm · Cited by 1
Improving Detection of Driver Genes: Power-Law Null Model of Copy Number Variation in Cancer
Loohuis, L. M. O., Witzel, A., & Mishra, B. (2014) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2014.2351805 · Cited by 1
DDRs: receptors that mediate adhesion, migration and invasion in breast cancer cells
Reyes-Uribe, E., Departamento de Biologia Celular, C.-I., Serna‐Marquez, N., & Salazar, E. P. (2015) · AIMS Biophysics · doi:10.3934/biophy.2015.3.303 · Cited by 1
Li–Fraumeni syndrome: a role for surgical pathologists?
Dickson, B. C. (2012) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2012.01.003 · Cited by 1
Interplay Between the Immunohistochemical Expression of P53 and the Proliferation Index in the Keratinocyte Tumors of the Skin
Rakočević, M., Jovicic, B. P., Jocić, T., Matić, S., Azanjac, G., Jovicic, N. U., Stanković, V., & Jančić, S. (2018) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2017-0020 · Cited by 1
Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes
Rhee, J., & Kim, T. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0352-z · Cited by 1
Analysis of tumor heterogeneity at the molecular level: a case report of efficacy separation in metastatic breast cancer
Li, X., Bian, L., Xu, F., Qu, Z., Yang, F., & Jiang, Z. (2020) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-20 · Cited by 1
Hidden Markov Modelling for Biological Sequence
Kannan, K. S., & Jeniffer, S. D. (2022) · Algorithms for intelligent systems · doi:10.1007/978-981-19-2126-1_31 · Cited by 1
Hereditary breast cancer
Lazarev, A. F., Zadontseva, N. S., & Gofman, A. A. (2014) · Russian Journal of Oncology · doi:10.17816/onco40062 · Cited by 1
ATM, RAD50 and p53 in breast cancer
Tommiska, J. (2008) · Työväentutkimus Vuosikirja · Cited by 1
Energy Generating Pathways and the Tumor Suppressor p53
Corcoran, C. A., Huang, Y. K., & Sheikh, M. S. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_8 · Cited by 1
Insights from a novel p53 isoform in zebrafish want to reel us in, but will we take the bait?: Figure 1.Preprint
Manfredi, J. J. (2009) · Genes & Development · doi:10.1101/gad.1778309 · Cited by 1
LUAD And LUSC Cancer Classification, Biomarker Identification, and Pathway Analysis Using Overlapping Feature Selection MethodsPreprint
Dhahbi, J. M., & Chen, J. W. (2021) · Research Square · doi:10.21203/rs.3.rs-151050/v1 · Cited by 1
Biomarkers in Head and Neck Cancer
Kang, H., Chung, C. H., & Forastiere, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-27601-4_7
Molecular markers in breast carcinoma. A study with focus on molecular phenotypes, angiogenesis and stem cells in an African population
Nalwoga, H. (2010) · NORA - Norwegian Open Research Archives
Análise da expressão de RNAs não-codificadores intrônicos em tumores de mama
Egídio, C. D. M. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2008.tde-08092008-155406
Nucleic Acid‐Based Markers in Urologic Malignancies
Wullich, B., Goebell, P. J., Taubert, H. W., & Wach, S. (2014) · Wiley eBooks · doi:10.1002/9783527672165.ch05
Wig-1: A p53 target that regulates the mRNA of p53 and Myc - and more?
Vilborg, A. (2010) · Figshare
(Epi-) genetic profiling of colorectal cancer : prognostic and biological relevance, with emphasis on tumor-hypoxia
Cleven, A. H. G. (2012) · doi:10.26481/dis.20120601ac
Characterization of a novel p63/p73 interacting protein.
Chiacchiera, F. (2008) · OpenstarTs (Univeristy of Trieste https://www.units.it/)
Modificadores de penetrância de mutações germinativas no gene TP53 em famílias brasileiras com diagnóstico clínico da síndrome de Li-Fraumeni e Li-Fraumeni like: impacto dos polimorfismos intragênicos do TP53 e de genes
Achatz, M. (2008) · doi:10.11606/t.5.2008.tde-29012009-172419
Self-citation
Is a TNF Alpha Polymorphism Responsible for Mutations in the TP53 Gene?
Berglund, M., Zainuddin, N., Thunberg, U., & Enblad, G. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02487.x
The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
Olivier, M., Hainaut, P. L., & Petitjean, A. (2007) · IATREIA
Self-citation
Predicting response: identifying molecular determinants of endocrine response and resistance in breast cancer
Butt, A. J. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.53
Understanding SNP — Gene associations in pancreatic cancer: A systems biology approach
Joseph, N., Gopakumar, G., Pradhan, M. P., Nazeer, K. A. A., & Palakal, M. J. (2015) · IEEE International Conference on Signal Processing, Informatics, Communication and Energy Systems (SPICES) · doi:10.1109/spices.2015.7091515
Significance of genetic instability in development and chemosensitivity of malignant tumors
Olasz, J. (2009) · Clinical and Experimental Medical Journal · doi:10.1556/cemed.3.2009.1.17
Gain-of-Function Effects of Mutant p53 Explored Using a Three-Dimensional Culture Model of Breast Cancer
Freed-Pastor, W. A. (2012) · doi:10.7916/d8zk5q1m
Tese apresentada com vistas à obtenção do título de Doutor em Ciências na área de Saúde Pública e Meio Ambiente.
Santos, S. D. S. (2013)
Granular Association Testing in p53 Multiple Sequence Alignment
Manjunath, R. (2012) · The Atrium (University of Guelph)
Differential flux balance analysis of quantitative proteomic data on protein interaction networks
Jiang, B., Gleich, D. F., & Gribskov, M. (2015) · IEEE Global Conference on Signal and Information Processing · doi:10.1109/globalsip.2015.7418343
The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
Santella, R. M. (2007)
Análisis de las aneuploidías del cromosoma 17 y deleción del gen TP53 en tumores gastrointestinales por FISH-bicolor Analyses of numerical aberrations of chromosome 17 And TP53 gene deletion in gastrointestinal tumors by dual-color fluorescence in situ hybridization (FISH)
Carlos, J., Patiño, H., Mario, C., Peña, M. G., Ricardo, J., Velásquez, M., & Jiménez, L. F. I. (2008)
Phytochemical Regulation of Tumor Suppressive MicroRNA in Human Breast Cancer Cells
Hargraves, K. G. H. (2013) · eScholarship (California Digital Library)
Estudo das alterações citogenômicas da medula óssea de trabalhadores rurais expostos a agrotóxicos
Filho, L. I. P. F. (2013)
Loss of BRCA1 in Normal Human Mammary Epithelial Cells Induces a Novel Mechanism of Senescence
Noor, S. (2011) · TSpace (University of Toronto)
Characterization and functional analysis of mutant p53 secretome in human cancer
Shakya, R. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/58d1bef2e0a57
Análisis de las aneuploidías del cromosoma 17 y deleción del gen TP53 en tumores gastrointestinales por FISH-bicolor Analyses of numerical aberrations of chromosome 17 And TP53 gene deletion in gastrointestinal tumors by dual-color fluorescence in situ hybridization (FISH)
Originales, T. (2008)
The Theoretical Prediction of the Mutagenic Regions of the p53 Tumor Suppressor Gene
Perez, J. C. (2018) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2018.08.555750
Somatic hematopoietic TP53 mosaicism in women with breast cancer exposed to ionizing radiation
Melnov, S., Murphy, P. D., Foley, T. P., Nadyrov, E. A., Kipen, V., Leushev, B., & Modugno, F. (2018) · The Breast Journal · doi:10.1111/tbj.13056
Molecular targets and targeted therapy
Dong, P. (2014) · doi:10.2217/fmeb2013.13.31
The biochemical functions of the Retinoblastoma binding protein 6 (RBBP 6) isoforms in metabolic reprogramming occurring during carcinogenesis
Nsingwane, Z. (2018)
Síndrome de Li-Fraumeni
Gómez, F. R., Ibáñez, R. D. M., Serrano, A. M., Dominguez, T. P., & Sánchez, J. C. P. (2019) · Cirugía Española · doi:10.1016/j.ciresp.2018.05.009
p53-Hsp90 Axis in Human Cancer
Ghaleb, A. M., & Marchenko, N. D. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_7
Análisis de los factores radiopatológicos del cáncer de mama triple negativo y determinación de perfiles de riesgo
Sebastián, C. S., Mur, C. G., Bañeres, B. G., Ciria, S. C., Cuesta, D. S. R., & Amador, I. S. (2020) · Radiología · doi:10.1016/j.rx.2020.01.001 · Cited by 1
Cancer Genomics
Spellman, P. T., Costello, J., & Gray, J. W. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10020-2
Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis.
Zhang, D., Wang, X., Ma, S., Li, P., Xue, F., Mao, B., Guan, X., Zhou, W., Peng, J., Su, K., et al. (2021) · PubMed Central · doi:10.3892/ol.2021.12440

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks